Redwood Bioscience Inc. doing business as Catalent Biologics – West, provides protein-chemical engineering for drug conjugate optimization. The Company has a site-specific protein modification policy that offers power over cargo placement on a protein, cargo alignment, and stoichiometry. Catalent Biologics – West attends customers in the United States.
In India, the business of Redwood Bioscience Inc. focuses on Hydrazinyl-pyrrole compounds and methods for producing a conjugate, ANTIBODY SPECIFIC FOR CD22 AND METHODS OF USE THEREOF, Hydrazinyl-pyrrole compounds and methods for producing a conjugate, Aldehyde-tagged immunoglobulin polypeptides and methods of use thereof and Anti-HER2 antibody-maytansine conjugates and methods of use thereof.
Redwood Bioscience Inc. filed a patent application numbered 3831/DELNP/2015 that is titled HYDRAZINYL -INDOLE COMPOUNDS AND CONJUGATES. The patent has been filed in the field of Chemicals. This Patent Application has been granted as Patent Number 351370. This invention provides conjugate structures (e.g., polypeptide conjugates) and hydrazinyl-indole compounds used to produce these conjugates. The discovery also offers systems of production for such conjugates and methods of exhausting the same.
During the patent examination, the Patent Examiner raised objections under Section 3(d) of the Indian Patents Act, 1970. It was pointed out that the structurally similar compound and the substitution in various positions are known from the cited prior arts. Hence, the core structure is known and the equivalent substitutions as taught by the cited document with other groups is considered a derivative of the known compound without any efficacy with reference to the prior arts. The compounds of the application are therefore considered derivatives of the known compounds without any therapeutic efficacy with reference to the cited one.
As a response, the Applicant submitted that the claimed invention is directed to polypeptide conjugates that include a modified amino acid residue of formula (I). In addition, the Applicant’s claimed invention is directed to compounds of formula (IV), such as intermediate compounds that can be used in the production of the conjugates of formula (I). Thus, the conjugates and compounds of the claimed invention are novel and inventive chemical entities that do not fall within the scope of Section 3(d).
Advocate Rahul Dev is a Patent Attorney & International Business Lawyer practicing Technology, Intellectual Property & Corporate Laws. He is reachable at rd (at) patentbusinesslawyer (dot) com & @rdpatentlawyer on Twitter.
Quoted in and contributed to 50+ national & international publications (Bloomberg, FirstPost, SwissInfo, Outlook Money, Yahoo News, Times of India, Economic Times, Business Standard, Quartz, Global Legal Post, International Bar Association, LawAsia, BioSpectrum Asia, Digital News Asia, e27, Leaders Speak, Entrepreneur India, VCCircle, AutoTech).
Regularly invited to speak at international & national platforms (conferences, TV channels, seminars, corporate trainings, government workshops) on technology, patents, business strategy, legal developments, leadership & management.
